Wednesday, October 19, 2016
Premier Research, a middle-market CRO that provides comprehensive clinical development, analytic and support services to pharmaceutical, biotech and medical device customers worldwide, will receive a growth investment from Metalmark Capital, a New York-based private equity firm, which acquired its position from Indigo Capital, a long-established, independently-owned investment firm based in London.
IMARC Research, a CRO based in Strongsville, Ohio, recently expanded its footprint in the medical device market by opening a new office in the Minneapolis area.
To meet the growing demand for preemptive pharmacogenomic risk factor screening that may one day aid drug prescription practices, Thermo Fisher Scientific has introduced PharmacoScan Solution, a new microarray-based research tool that contains pharmacogenomic content with relevant markers involved in absorption, distribution, metabolism and excretion (ADME) pathways of commonly prescribed medicines.
Parexel International, a global biopharmaceutical services organization, has launched its Active Tracking service. The service follows Good Distribution Practice (GDP) requirements by providing biopharmaceutical companies with near real-time temperature and location monitoring of investigational medicinal products (IMPs) from central distribution centers to clinical trial sites.
Quintiles IMS Holdings has successfully completed its merger of equals transaction between IMS Health Holdings and Quintiles Transnational Holdings. The merger of IMS Health, a global information and technology services company, and Quintiles, a provider of product development and integrated healthcare services, creates an information and tech-enabled healthcare service provider with global scale and reach, and a full suite of end-to-end clinical and commercial offerings.
PathoQuest, a rapidly growing biotechnology company spun out from Institut Pasteur, has announced a preferred partnership with Charles River Laboratories, an early-stage CRO, to provide an improved Viral Safety Service offering to biopharmaceutical companies. While traditional molecular approaches to safety testing are limited to the identification of a limited, predefined list of viruses, the PathoQuest’s next generation sequencing (NGS) solution combines a proprietary curated virus database with an automated analysis pipeline. This provides a universal test for identifying viruses of any type in a single, comprehensive analysis that minimizes false negatives.
Charles River Laboratories International has acquired Agilux Laboratories, a Worcester, Massachusetts-based CRO that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic (DMPK) services and pharmacology services. The company’s unique combination of early-stage services enhances the flexibility and speed of its biopharmaceutical clients’ lead identification, optimization, and candidate selection efforts. Agilux was acquired from a holding company controlled by the company’s founders and Ampersand Capital Partners, its only institutional investor.
Worldwide Clinical Trials, a full-service CRO, has opened a new office in the heart of Warsaw’s central business district. Home to 30+ employees, the 315m2 office space in the Prosta Tower boasts state-of-the-art technology and design, supporting a collaborative, productive work environment.
Parexel International, a global biopharmaceutical services provider, has entered into a definitive agreement to acquire ExecuPharm, a global functional service provider (FSP) serving the biopharmaceutical industry. The acquisition is expected to close in the next three weeks. Terms of the transaction were not disclosed.